Mode
Text Size
Log in / Sign up
Phase 4 N=114 Randomized Quadruple-blind Treatment

Metformin Postpartum for GDM RCT for Reduced Weight Retention

Diabetes, Gestational

Enrolled (actual)
114
Serious AEs
0.0%
Results posted
Nov 2018
Primary outcome: Primary: Weight Change — 6.5; 6.3 kg

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Metformin (Drug); Placebo (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
The University of Texas Health Science Center, Houston
Primary completion
Mar 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Weight Change
6.5; 6.3
SECONDARY
Number of Participants Who Achieved Pre-pregnancy Weight
16; 15
SECONDARY
Number of Participants Who Achieved Their Ideal Body Weight
1; 1
SECONDARY
Hemoglobin a1c
SECONDARY
HDL, LDL, Triglyceride
SECONDARY
Self-reported Compliance With Medications
0; 0; 1; 1; 14; 18
SECONDARY
Self-reported Compliance With Medications
0; 0; 1; 1; 14; 18
SECONDARY
Difficulty With Diet as Assessed by a 5-point Likert Scale
10; 9; 9; 10; 14; 14
SECONDARY
Difficulty With Exercise as Assessed by a 5-point Likert Scale
11; 11; 9; 6; 13; 13
SECONDARY
Difficulty With Medication as Assessed by a 5-point Likert Scale
15; 14; 7; 6; 5; 7
SECONDARY
Satisfaction With Diet as Assessed by a 5-point Likert Scale
2; 6; 5; 7; 9; 8
SECONDARY
Satisfaction With Exercise as Assessed by a 5-point Likert Scale
3; 6; 9; 6; 14; 14
SECONDARY
Satisfaction With Medication as Assessed by a 5-point Likert Scale
4; 5; 6; 4; 6; 7

Summary

The purpose of this study is to determine whether the study drug metformin is helpful in reducing weight after pregnancy in women with gestational diabetes. This pilot study will provide information on how well women are able to take metformin postpartum, whether metformin increases weight loss, and whether there are any increased risks of side effects to you as a new mother.

Eligibility Criteria

Inclusion Criteria

  • Postpartum women with a delivery greater than 34 weeks of pregnancy
  • Between the ages of 18 to 49 years
  • Women with a diagnosis of gestational diabetes mellitus (either treated with insulin, oral hypoglycemic agent or diet-controlled) after 24 weeks in most recent pregnancy based on a confirmatory 3 hour glucola test (based on either the Carpenter and Coustan's of the Diabetes Task Force criteria)

Exclusion Criteria

  • women with pre-gestational diabetes mellitus (either Type I or Type II DM)
  • women unable to tolerate metformin based on patient history
  • women who will be discharged hom eon insulin or oral hypoglycemic agent in the immediate postpartum period
  • women with a BMI <25 kg/m²
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01280409). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search